Literature DB >> 33628853

Moesin Is a Novel Biomarker of Endothelial Injury in Sepsis.

Yikun Chen1, Jiajia Wang1, Lei Zhang2, Jianjie Zhu1, Yuanyuan Zeng1, Jian-An Huang1.   

Abstract

OBJECTIVE: Increased vascular permeability and inflammation are principal hallmark of sepsis. Moesin (MSN) is a membrane-associated cytoskeleton protein and crucial for the vascular endothelial function. This study is aimed at evaluating the role of MSN in endothelial injury during the process of sepsis.
METHODS: Serum MSN in septic patients was measured by ELISA. BALB/c mice were injected with different doses of lipopolysaccharide (LPS) or underwent cecal ligation and single or double puncture (CLP) to mimic sublethal and lethal sepsis. After treatment, their serum MSN and PCT levels, wet to dry lung weights (W/D ratio), bronchoalveolar lavage fluid (BALF) protein concentrations, and lung injury scores were measured. The impact of MSN silencing on LPS-altered Rock1/myosin light chain (MLC), NF-κB, and inflammatory factors in human microvascular endothelial cells (HMECs), as well as monolayer HMEC permeability, was tested in vitro.
RESULTS: Compared with healthy controls, serum MSN increased in septic patients and was positively correlated with SOFA scores and serum PCT levels in septic patients. LPS injection significantly increased serum the MSN and PCT expression, BALF protein levels, and W/D ratio, and the serum MSN levels were positively correlated with serum PCT, lung W/D ratio, and lung injury scores in mice. Similar results were obtained in the way of CLP modelling. LPS enhanced MSN, MLC, NF-κB phosphorylation, increased Rock1 expression, and inflammatory factors release in the cultured HMECs, while MSN silencing significantly mitigated the LPS-induced Rock1 and inflammatory factor expression, NF-κB, and MLC phosphorylation as well as the monolayer hyperpermeability in HMECs.
CONCLUSIONS: Increased serum MSN contributes to the sepsis-related endothelium damages by activating the Rock1/MLC and NF-κB signaling and may be a potential biomarker for evaluating the severity of sepsis.
Copyright © 2021 Yikun Chen et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33628853      PMCID: PMC7896848          DOI: 10.1155/2021/6695679

Source DB:  PubMed          Journal:  J Immunol Res        ISSN: 2314-7156            Impact factor:   4.818


  34 in total

1.  Cell surface-expressed moesin-like receptor regulates T cell interactions with tissue components and binds an adhesion-modulating IL-2 peptide generated by elastase.

Authors:  A Ariel; R Hershkoviz; I Altbaum-Weiss; S Ganor; O Lider
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

2.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

3.  Phosphorylated ERM Mediates Lipopolysaccharide Induced Pulmonary Microvascular Endothelial Cells Permeability Through Negatively Regulating Rac1 Activity.

Authors:  Liming Fei; Gengyun Sun; Zhongming Zhu; Qinghai You
Journal:  Arch Bronconeumol (Engl Ed)       Date:  2018-11-15       Impact factor: 4.872

4.  Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury.

Authors:  Bernard J Fisher; Ignacio M Seropian; Donatas Kraskauskas; Jay N Thakkar; Norbert F Voelkel; Alpha A Fowler; Ramesh Natarajan
Journal:  Crit Care Med       Date:  2011-06       Impact factor: 7.598

5.  Human and experimental septic shock are characterized by depletion of lipid droplets in the adrenals.

Authors:  Andrea Polito; Geoffroy Lorin de la Grandmaison; Arnaud Mansart; Estelle Louiset; Hervé Lefebvre; Tarek Sharshar; Djillali Annane
Journal:  Intensive Care Med       Date:  2010-07-28       Impact factor: 17.440

6.  In-depth proteomics approach of secretome to identify novel biomarker for sepsis in LPS-stimulated endothelial cells.

Authors:  Oh Kwang Kwon; Wonhwa Lee; Sun Ju Kim; You-Mie Lee; Ju Yeon Lee; Jin Young Kim; Jong-Sup Bae; Sangkyu Lee
Journal:  Electrophoresis       Date:  2015-09-13       Impact factor: 3.535

7.  Moesin becomes linked to the plasma membrane in attached neutrophil granulocytes.

Authors:  M Keresztes; Z Lajtos; J Fischer; L Dux
Journal:  Biochem Biophys Res Commun       Date:  1998-11-27       Impact factor: 3.575

8.  Sepsis-3 Septic Shock Criteria and Associated Mortality Among Infected Hospitalized Patients Assessed by a Rapid Response Team.

Authors:  Shannon M Fernando; Peter M Reardon; Bram Rochwerg; Nathan I Shapiro; Donald M Yealy; Andrew J E Seely; Jeffrey J Perry; Douglas P Barnaby; Kyle Murphy; Peter Tanuseputro; Kwadwo Kyeremanteng
Journal:  Chest       Date:  2018-05-17       Impact factor: 9.410

9.  Biomarkers of inflammation and the etiology of sepsis.

Authors:  Inge Grondman; Andrei Pirvu; Anca Riza; Mihai Ioana; Mihai G Netea
Journal:  Biochem Soc Trans       Date:  2020-02-28       Impact factor: 5.407

10.  Myosin di-phosphorylation and peripheral actin bundle formation as initial events during endothelial barrier disruption.

Authors:  Mayumi Hirano; Katsuya Hirano
Journal:  Sci Rep       Date:  2016-02-11       Impact factor: 4.379

View more
  2 in total

1.  The ROCK-ezrin signaling pathway mediates LPS-induced cytokine production in pulmonary alveolar epithelial cells.

Authors:  Ning Ding; Pibao Li; Huiqing Li; Yunlong Lei; Zengzhen Zhang
Journal:  Cell Commun Signal       Date:  2022-05-12       Impact factor: 7.525

2.  SOFA Score in relation to Sepsis: Clinical Implications in Diagnosis, Treatment, and Prognostic Assessment.

Authors:  Changbo Liu; Shuzhen Suo; Liya Luo; Xixian Chen; Chunxiang Ling; Shixiong Cao
Journal:  Comput Math Methods Med       Date:  2022-08-10       Impact factor: 2.809

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.